Last reviewed · How we verify
A Phase 1 Dose Escalation and Safety Study of NXC-201 (formerly HBI0101) CART in BCMA-Expressing Multiple Myeloma Patients
It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients
Details
| Lead sponsor | Hadassah Medical Organization |
|---|---|
| Phase | Phase 1 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 160 |
| Start date | 2021-01-01 |
| Completion | 2027-01 |
Conditions
- Dose Escalation and Safety
Interventions
- NXC-201 (formerly HBI0101)
Primary outcomes
- Determination of MTD — 21 days
Part A: Determination of MTD Part B: Confirmation of selected dose tested (at or below MTD) ( safety )
Countries
Israel